TKT management additions
Former Biogen VP-Development & Quality David Pendergast, PhD, is appointed TKT senior VP-quality & analytical development, replacing VP Joseph Habarta, PhD. Pendergast reports to CEO Richard Selden, MD/PhD. At Biogen, Pendergast is replaced by Sylvie Gregoire, who is promoted to exec VP-technical operations. Another Biogen alum and former Vertex Program Executive Neil Kirby, PhD, joins TKT as VP-global regulatory affairs, replacing Kurt Gunter, MD. Kirby reports to General Counsel Michael Astrue...
You may also be interested in...
Novavax aims to recruit 10,000 subjects in the UK, and will include a flu vaccination co-administration for some participants.
Accord has launched its first monoclonal antibody biosimilar and fourth biosimilar overall, introducing in the UK the Zercepac version of trastuzumab developed by China’s Shanghai Henlius Biotech.
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.